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ABSTRACT 
Confirmed cases of porcine circovirus disease (PCVD) in GB have shown a steady decline 
since the availability of porcine circovirus 2 (PCV2) vaccines. However, PCVD is still 
sporadically diagnosed. We carried out a genotyping study to characterise PCV2 associated 
with confirmed PCVD cases in England and Wales from 2011 to January 2016 (n=65). A 
partial fragment of PCV2 genome encompassing open reading frame 2 (ORF2) was amplified 
and sequenced from 45 cases of PCVD. The majority of sequences were genotype PCV2b but 
four sequences were PCV2d. The significance of the emergence of PCV2d in England and 
elsewhere in the world is not yet known but may represent a global genotype shift. 
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INTRODUCTION 
Disease associated with porcine circovirus 2 (PCV2) emerged in pigs in England from 1999 
manifesting mainly as postweaning multisystemic wasting syndrome (PMWS). It rapidly 
became a significant cause of economic loss to the pig industry, due to both the effects of 
disease on pig productivity, health and welfare and the costs relating to interventions to 
treatment and control (Alarcon and others 2013). Following its initial emergence and spread, 
the clinical and pathological presentations of porcine circovirus diseases (PCVD) have become 
more diverse with enteric, hepatic, respiratory and even, nervous presentations described 
(Segales 2012). The pathogenesis of PCVD is still not fully understood; however the 
availability of commercial PCV2 vaccines in the UK since 2006  has effected a dramatic 
reduction on the impact of this viral infection (Chae 2012). Vaccination is widespread in 
commercial pig herds in Great Britain and has proven effective in improving health and 
productivity through control of clinical disease and subclinical effects (Kurmann and others 
2011) (Young 2011). 
PCV2 was first characterised in 1998 and subsequent analyses, including retrospective analyses 
showed that PCV2a predominated in the pig population initially but there was then a global 
genotype shift from PCV2a to PCV2b around 2003 (Beach and Meng 2012). Currently there 
are four recognised PCV2 genotypes, PCV2a, PCV2b, PCV2c and PCV2d. Interestingly, 
PCV2d was referred initially to as mutant PCV2b (Guo and others 2012) and has recently been 
reclassified as PCV2d (Xiao and others 2015). Based on these genotypic changes analysed, it 
appears that there may now be an ongoing global genotype shift from PCV2b to PCV2d (Xiao 
and others 2015). Furthermore, a fifth genotype, PCV2e has recently been proposed, based on 
the analysis of 10 novel sequences that were obtained from samples from 2006-2015 from the 
US and Mexico (Davies and others 2016). Until very recently PCV2c had only been detected 
in archived samples from Denmark (1980, 1987 and 1990) but there is now a report that it is 
circulating in feral pigs in Brazil (Franzo and others 2015a). There is no evidence that PCV2c 
is currently circulating in the commercial pig population.  
There is no information available regarding the genotype of PCV2 currently circulating in the 
pig population in GB. Data obtained during the Royal Veterinary College (RVC) PMWS 
project (Alarcon and others 2011) had found that in 2008-2009, PCV2b was the main genotype 
circulating in pigs in England (D. Werling, personal communication). 
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The annual diagnostic rate of PCVD in GB has shown a steady decline. Occasional incidents 
are still diagnosed, which arise in either unvaccinated pigs or in herds where it was known, or 
strongly suspected, that groups of pigs had inadvertently not been vaccinated or had some other 
vaccine administration issue (APHA 2014). These incidents include some with unusual 
presentations, such as foetopathy (APHA 2015). Occasionally, incidents have been diagnosed 
where no reason was identified for the occurrence of PCVD in vaccinated pigs (Florins and 
others 2007). In order to investigate PCVD incidents, and obtain genotyping information for 
surveillance purposes, viruses associated with confirmed PCVD cases in England and Wales 
from 2011 to 2016 were characterised. 
MATERIAL AND METHODS 
The study investigated 65 diagnostic submissions submitted to the Animal and Plant Health 
Agency (APHA) Veterinary Investigation Centres from 2011 to January 2016 with confirmed 
diagnosis of PCVD. Diagnostic criteria for an individual pig were based on Sorden (2000) and 
Opriessnig and others (2007). They comprise of three components, all of which must be 
present; clinical signs, histological lesions (lymphoid depletion of tissue and/or histiocytic 
inflammation) and the presence of PCV2 antigen associated with the microscopic lesions. 
For submissions from 2011-2013, one sample (one pig) per submission was investigated for 
this study while between 1 and 3 samples (from different pigs) were investigated for 
submissions from 2014-2016. Lymph node samples were used in preference to other tissues 
where available; otherwise, lung or heart samples were used. Samples were available either as 
sections cut from paraffin-embedded tissue blocks (PETB) or fresh tissues stored frozen at 
minus 20oC from most recent cases. When sections were cut from PETB, precautions were 
taken including use of new microtome blades for each sample to prevent cross contamination. 
Nucleic acid was extracted from PETB as described previously (Grierson and others 2004a). 
Digestion of the PETB sections was performed using Proteinase K (Ambion) in a digestion 
buffer composed of 100mM NaCl, 0.5% SDS, 10mM Tris-HCl (pH 8) and 1mM EDTA (pH 
8). Nucleic acid was extracted from tissue using the QIAamp DNA Mini kit (Qiagen), and 
performed according to manufacturer’s instructions. A 704bp fragment of the PCV2 genome, 
encompassing the entire coding sequence of open reading frame 2 (ORF2) was amplified using 
primers described in Fort and others (2007). The resulting amplicon was analysed by Sanger 
sequencing: phylogenetic analysis of ORF2 is representative of whole genome analysis (Olvera 
and others 2007). Sequences were assembled using SeqMan™ (DNASTAR) and subsequently 
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aligned using MegAlign™ (DNASTAR). Reference genotypes (PCV2a-PCV2d; Franzo and 
others 2015b) and proposed genotype PCV2e sequences (Davies and others 2016) were 
included in the sequence analysis. In addition, 30 PCV2b ORF2 sequences acquired during the 
RVC PMWS project (BB/FO18394/1) were included in the analysis (KY806000-KY806029). 
These sequences were obtained from samples collected in 2008-2009 from PMWS affected 
farms in England. Genetic distances were calculated using MEGA5 (Neighbor-Joining) 
(Tamura and others 2011).  
RESULTS 
ORF2 sequences were obtained from 45 of the 65 submissions tested (Table 1). In most cases, 
sequence obtained from more than one sample (pig) in a single submission were found to be 
identical, except for three instances for which two unique sequences were obtained (99.0-
99.3% identity within a submission). A total of 48 sequences were obtained from 45 
submissions (Table 1). All but four of the 48 ORF2 sequences were 702 nucleotides in length 
and encoding for a protein of 234 amino acids. Nucleotide sequence identity of these 44 
sequences ranged from 92.6-100% (40 unique sequences; Genbank accession KY806070-
KY806071). Phylogenetic analysis showed that sequences clustered with reference PCV2b 
strains and that there was no obvious clustering of sequences relative to those obtained from 
pigs in England in 2008-2009 (Figure 1). 
Four sequences were 705 nucleotides in length as a result of a substitution in the stop codon 
and that encoded for an additional amino acid (Lysine). Nucleotide sequence identity of these 
four sequences ranged from 99.9-100% (2 unique sequences; Genbank accession KY806070-
KY806071). These sequences clustered within genotype PCV2d (Figure 1). 
Disease presentation for the majority of the 45 confirmed PCVD diagnoses comprised of 
typical PMWS clinical signs (wasting, with or without respiratory signs, with or without 
diarrhoea,). However, two submissions were of reproductive disease (one has been reported 
elsewhere (APHA 2015)). Both instances of reproductive disease were associated with PCV2b. 
Information on farm PCV2 vaccination status was available for only 23 of the 45 submissions 
from which sequence data were obtained, and of these52% of farms (12 of 23) did not 
vaccinate. Of the four submissions in which PCV2d was detected, three farms vaccinated (at 
6-8 weeks of age), whereas the status of the fourth was unknown. The pigs in which PCV2d 
was detected were from farms in North Yorkshire and East Anglia. 
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DISCUSSION 
It has been estimated that PCV2d originated around 20 years ago (Xiao and others 2015). 
However, it appears that its prevalence has increased in China (Cai and others 2012), and there 
are now increasing reports of its detection in North America, South America and Europe. 
Indeed, the virus was retrospectively detected in a sample from 1999 from Switzerland (Xiao 
and others 2015) and has been sporadically detected since then in countires such as Netherlands 
(2001-2002; (Grierson and others 2004b), China (2002) and Germany (Xiao and others 2015). 
The reports suggest there is a steady emergence of PCV2b and a slow genotypic shift from 
PCV2b to PCV2d (Xiao and others 2015). The sample set in this study is not yet sufficient to 
state that there is an increased trend of PCV2d in England and Wales, but continued monitoring 
of the PCV2 genotype from disease incidents may allow analysis in the future. PCV2d was 
detected in a sample from one pig farm from 2013 and three samples derived from two farms 
from 2014. The absence of detection in samples from 2015 and 2016 may simply be due to the 
small sample sizes (six and one submission diagnosed with PCVD respectively). The four 
PCV2d ORF2 sequences from 2013 and 2014 share high nucleotide identity and indeed three 
of the four were identical in ORF2 sequence. The PCV2d sequences were from two regions of 
England: the study analysed samples that had been submitted to eleven APHA Veterinary 
Investigation Centres.  
The significance of the apparent emergence of PCV2d pigs in England is not yet known. There 
are currently conflicting evidence with regard to potential differences in virulence relative to 
PCV2a and PCV2b. Guo et al. (2012) reported enhanced virulence in weaned, 30-day old 
commercial piglets (more severe signs compatible with PMWS; more severe pathological 
lesions and higher viral loads; lower average daily weight gain) relative to challenge with 
PCV2a and PCV2b. Yet Opriessnig et al. (2014b) found no significant difference in virulence 
although they did not rule out there being some difference.  
It has to be stressed that all licensed vaccines, despite being based on on the PCV2a genotype, 
show cross-protection against PCV2b (Fort and others 2008) and PCV2d (Opriessnig and 
others 2014a). Interestingly, PCV2d strains characterised from 1999 and 2001/2002 were from 
healthy pigs (Grierson and others 2004b; Xiao and others 2015) and indeed strain NL-control-
4 was from a farm that had no history of PMWS or porcine dermatitis and nephropathy 
syndrome (PDNS) (Grierson and others 2004b). Reports of the detection of PCV2d have been 
associated with apparent vaccine breakdown and consequently the cross-protectiveness of the 
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PCV2a based vaccines was questioned (Opriessnig and others 2013b). However, as stated 
above, PCV2a-based vaccines have been shown to protect against PCV2d challenge 
(Opriessnig and others 2014a). To date there is no evidence that current vaccines are not 
effective against the circulating PCV2 genotypes in controlling disease, although they may be 
less effective in reducing the amount of virus (Opriessnig and others 2013a). It should be noted 
that instances of apparent vaccine failure may be due to issues related to the storage, handling, 
administration or timing of vaccination rather than a true lack of vaccinal efficacy. Also 
assessing the virulence of PCV2 strains in the field is not possible because of the variation in 
environment, management, concurrent pathogens and other factors influencing the severity of 
PCVD in pigs. 
PCR products for sequencing were not obtained from 20 of the submissions tested although 
PCV2 was known to be present from histopathological and immunohistochemical 
investigations. This is not unexpected as a relatively large fragment of the PCV2 genome is 
amplified for characterisation (~740bp) and which reduces the sensitivity of detection of the 
PCR. The quality of the DNA extracted from the PETB will also have affected the ability to 
obtain PCR product and which will be affected by the sample quality prior to fixation and 
embedding amongst other factors (Grierson and others 2004a).  
Although vaccination is effective in controlling disease it does not prevent virus infection 
establishing, therefore PCV2 infection will continue to circulate in the pig population albeit at 
a lower rate. APHA will continue to monitor for any change in clinical or epidemiological 
presentation of PCVD or vaccination failure in pigs in England and Wales. 
 
8 
 
ACKNOWLEDGEMENTS 
This work was funded by Defra within the APHA project “Scanning surveillance for pig 
diseases in England and Wales (ED1200)”. The expertise of APHA veterinary and scientific 
colleagues in the Veterinary Investigation Centres and Lasswade is acknowledged as is the 
provision of diagnostic material to APHA by submitting private veterinary practitioners and 
their pig keeping clients. Archived samples from the RVC were a result of a grant 
(BB/FO18394/1) funded through the the BBSRC ‘Combating Endemic Diseases of Farmed 
Animals for Sustainability’ (CEDFAS) initiative, with contributions from BPEX, Biobest 
Laboratories and Zoetis Animal Health.We would like to thank Marie Walker (Lasswade) for 
organising the PETB sections for this study. 
9 
 
TABLE 1 Characterisation of ORF2 of PCV2 in cases of PCVD in England and Wales 
Year No.  
Submissions 
tested 
No. 
Submissions 
from which 
sequence(s) 
obtained 
PCV2b PCV2d 
No.  
Submissions 
No. 
Sequences 
(unique 1) 
No. 
Submissions 
No. 
Sequences 
(unique 1) 
2011 18 11 11 11 (8) 0 0 
2012 14 9 9  9  0 0 
2013 11 7 6 6 1 1 
2014 15 13 10 11 2 (10) 3 3 (2) 
2015 6 4 4 6 3 0 0 
2016 1 1 1 1 0 0 
Total 65 45 41 44 (40) 4 4 (2) 
No., number 
1 Number of unique sequences per year if different to the No. Sequences 
2 Two unique sequences from one submission 
3 Two unique sequences from each of two submissions
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FIGURE 1 Phylogenetic dendrogram depicting genetic distance based on the complete 
coding sequence of ORF2 (702-708nt). Sequences were aligned using MegAlign 
(DNASTAR) and genetic distances calculated using MEGA5 (Neighbor-Joining). Analysis 
includes 902 reference genotypes (PCV2a-PCV2d) (Franzo and others 2015b) and 10 
proposed genotype PCV2e sequences (Davies and others 2016). Study sequences are 
indicated (). Sequences from samples collected in England in 2008-2009 (RVC PMWS 
PROJECT) are indicated ().  
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